Abstract #3891

Detection of recurrent prostate cancer with 18F-Fluciclovine PET/MRI

Kirsten Margrete Selnæs^1,2, Mattijs Elschot¹, Brage Krüger-Stokke^1,3, Håkon Johansen⁴, Per Arvid Steen³, Sverre Langørgen³, Bjørg Yksnøy Aksnessæther⁵, Gunnar Indrebø⁵, Torill Anita Eidhammer Sjøbakk¹, May-Britt Tessem¹, Siver Andreas Moestue¹, Heidi Knobel⁶, Torgrim Tandstad⁶, Helena Bertilsson^7,8, Arne Solberg⁶, and Tone Frost Bathen^1,2

¹Department of Circulation and Medical Imaging, NTNU- Norwegian University of Science and Technology, Trondheim, Norway, ²St. Olavs Hospital, Trondheim University Hospital, Trondheim, Norway, ³Department of Radiology, St. Olavs Hospital, Trondheim University Hospital, ⁴Department of Nuclear Medicine, St. Olavs Hospital, Trondheim University Hospital, ⁵Ålesund sjukehus, Helse Møre og Romsdal HF, ⁶Department of Oncology, St. Olavs Hospital, Trondheim University Hospital, ⁷Department of Urology, St. Olavs Hospital, Trondheim University Hospital, ⁸Department of Cancer Research and Molecular Medicine, NTNU- Norwegian University of Science and Technology, Trondheim, Norway

Simultaneous PET/MRI has the potential to improve the detection accuracy in recurrent prostate cancer, since it combines the excellent soft-tissue contrast of MRI with the high molecular sensitivity of PET in one imaging session. The aim of this observational study is to assess the detection rate of recurrent prostate cancer by simultaneous ¹⁸F-Fluciclovine PET/MRI. We demonstrate that18F-Fluciclovine PET/MRI can detect suspicious lymph node, prostatic and bone lesions in patients with a wide range of PSA levels and that the number of equivocal findings is reduced when MR images are evaluated in conjunction with PET uptake. .

This abstract and the presentation materials are available to members only; a login is required.

Join Here